Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Res. 2012 Jul 19;72(17):4483–4493. doi: 10.1158/0008-5472.CAN-12-0283

Figure 4. Analyses of MK-2206 and MK-8669 on human prostate cancer cells.

Figure 4

(A) Western blot analyses of protein extracts from PC3 or LNCaP cells, as indicated, showing the expression levels of the indicated phospho-proteins following treatment with agents, as indicated, for 24 hours. (B) Western blot analyses of PC3 cells incubated with the control or Rictor siRNA for 24 hours, followed by treatment with the agents as indicated for an additional 24 hours. (C) Western blot analyses of PC3 cells showing the expression levels of the indicated phospho-proteins following treatment with the agents, as indicated, for 24 hours. (D) Cell growth assay. PC3 cells were seeded at low density (200,000/35 mm dish) on day 0 and then treated on day 1 with vehicle or MK-2206 (1 μM) and/or MK-8669 (1 nM). Cell numbers were assessed by counting with trypan blue. (E) Flow cytometry analyses of PC3 cells showing the percentage of cells in the G1 phase following treatment with the indicated drug for 24 hours; similar results were obtained following incubation for 48 hours.